Palatin Technologies, Inc. — Form 10-K Summary
Business context and reporting period
The filing is an annual report for the fiscal year ended June 30, 2012, not a 2011 quarterly filing. It includes unaudited fourth-quarter fiscal 2012 data. Palatin is a development-stage biopharmaceutical company with no approved products; its lead candidate is bremelanotide for female sexual dysfunction (FSD). Other programs include PL-3994 for pulmonary and cardiovascular indications and melanocortin compounds licensed to AstraZeneca for obesity-related indications.
Financial performance and liquidity
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $73,736 | $1.48 million |
| Research and development expense | $13.81 million | $10.38 million |
| General and administrative expense | $5.05 million | $4.75 million |
| Net loss | $17.25 million | $12.82 million |
| Net loss per share | $0.49 | $0.64 |
| Cash used in operating activities | $15.49 million | $11.03 million |
- Revenue fell sharply, mainly because FY2011 included a $977,917 federal grant and FY2010 had included substantial AstraZeneca license revenue. FY2012 revenue was principally AstraZeneca reimbursement.
- R&D costs rose largely due to the ongoing Phase 2B bremelanotide trial. The company reported no meaningful product-sales base from which to assess operating margins.
- At June 30, 2012, cash and cash equivalents were $3.83 million; current assets were $4.74 million and current liabilities were $3.46 million. Stockholders’ equity was $1.83 million. Total liabilities were $3.55 million, including approximately $42,000 of capital lease obligations; the filing reports no material conventional debt balance.
- On July 3, 2012, after year-end, Palatin completed a private placement with $35.0 million gross and approximately $34.5 million net proceeds. Including those proceeds, the company described pro forma cash as approximately $38.3 million.
Material changes, outlook, and risks
- The last patient had completed treatment in the Phase 2B FSD trial. Palatin expected database lock by the end of September 2012 and top-line results in the first half of calendar Q4 2012. Advancement to Phase 3 depended on the trial results; Phase 3 was expected to require substantial additional capital.
- Management said available working capital, assuming stockholder approval of an increase in authorized shares, was expected to fund planned operations through at least calendar 2013. It also stated that current resources were insufficient to complete the clinical trials required for product approval and that additional financing or partnering would be needed.
- The auditor issued an unqualified opinion but highlighted substantial doubt about Palatin’s ability to continue as a going concern, citing recurring losses, negative operating cash flows, future financing needs, and contingent obligations from the July financing.
- The July placement included 3.873 million common shares and warrants for up to 31.99 million additional shares (Series A) and 35.49 million (Series B), generally exercisable at $0.01 per share. Series B warrants depended on stockholder approval to increase authorized shares. Failure to obtain approval by specified dates could trigger 10% annual interest, with a stated minimum annual payment of about $1.77 million, and holder redemption rights with no stated upper limit on the price. The filing warns Palatin might lack funds to meet redemption demands.
- Until the authorized-share increase, a portion of Series B warrants could be treated as a fair-value liability, with changes affecting reported earnings and equity. The company warned this could jeopardize NYSE MKT continued-listing compliance. The financing also imposes restrictions on future financing and gives purchasers specified negotiation and participation rights.
- AstraZeneca discontinued AZD2820 after a Phase 1 trial was halted following a serious adverse event; the company said other collaboration compounds remained under preclinical evaluation. Nasal bremelanotide development had previously been discontinued after blood-pressure increases and nausea/vomiting concerns; the ongoing FSD program uses subcutaneous delivery.
- Other key risks include clinical and regulatory failure, dependence on outside trial and manufacturing providers, limited cash runway, competition, uncertain reimbursement, patent risks, and significant potential dilution. The company said it expected additional losses for at least the next few years.
Most important facts for investors to verify
- Whether stockholders approved the authorized-share increase scheduled for September 27, 2012, and the resulting status of Series B warrant interest, redemption, and accounting treatment.
- The Phase 2B bremelanotide results, safety findings, and whether the program advanced toward Phase 3.
- Actual cash runway and the timing, amount, and terms of additional financing or partnering needed for Phase 3 and other programs.
- The potential dilution and financing constraints associated with the outstanding and newly issued warrants, including any impact on exchange-listing compliance.
- Progress and funding commitments under the AstraZeneca collaboration and development plans for PL-3994.